Faricimab
- Generic Name
- Faricimab
- Brand Names
- Vabysmo
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1607793-29-2
- Unique Ingredient Identifier
- QC4F7FKK7I
- Background
Retinal vascular diseases (RVDs) such as diabetic macular edema (DME), age-related macular degeneration (AMD), and retinal vein occlusion (RVO) are typically caused by retinal ischemia and subsequent neovascularization (NV). Vascular endothelial growth factor A (VEGF-A) is a well-known mediator of retinal NV, and many currently approved RVD therapies such as...
- Indication
Faricimab is indicated for the treatment of neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME).
- Associated Conditions
- Diabetic Macular Edema (DME), Neovascular Age-Related Macular Degeneration (nAMD), Visual Impairment
- Associated Therapies
- -
A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema
- Conditions
- Interventions
- First Posted Date
- 2018-08-09
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 951
- Registration Number
- NCT03622593
- Locations
- 🇨🇦
Toronto Retina Institute, Toronto, Ontario, Canada
🇨🇦Unity Health Toronto, Toronto, Ontario, Canada
🇺🇸Retina Consultants of Nevada, Las Vegas, Nevada, United States
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration
- Conditions
- Interventions
- First Posted Date
- 2017-02-01
- Last Posted Date
- 2021-01-05
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 76
- Registration Number
- NCT03038880
- Locations
- 🇺🇸
Retinal Consultants of Arizona, Phoenix, Arizona, United States
🇺🇸California Retina Consultants, Bakersfield, California, United States
🇺🇸Rand Eye, Deerfield Beach, Florida, United States
A Study of Faricimab (RO6867461) in Participants With Center-Involving Diabetic Macular Edema
- First Posted Date
- 2016-03-04
- Last Posted Date
- 2020-09-25
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 229
- Registration Number
- NCT02699450
- Locations
- 🇺🇸
United Med Res Inst, Inglewood, California, United States
🇺🇸Ophthalmic Clinical Trials San Diego, Oceanside, California, United States
🇺🇸Southern CA Desert Retina Cons, Palm Desert, California, United States
A Proof-of-Concept Study of Faricimab (RO6867461) in Participants With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)
- Conditions
- Interventions
- First Posted Date
- 2015-06-30
- Last Posted Date
- 2020-11-12
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 273
- Registration Number
- NCT02484690
- Locations
- 🇺🇸
Retina Consultants, San Diego, Poway, California, United States
🇺🇸New England Retina Associates, Hamden, Connecticut, United States
🇺🇸Austin Retina Associates, Austin, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.